Results 131 to 140 of about 5,427 (186)

Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo. [PDF]

Cancer Res Commun
Traichel J, Metzger A, Walz M, Feuerstein R, Wohlfeil N, Metzger P, Marx L, Asdih C, Lindenthal A, Seger A, Schrimpf J, Nardella LL, Kowar S, Frew IJ, Halbach S, Kesselring R, Boerries M, Griffin R, Brummer T.   +18 more
europepmc   +1 more source

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study. [PDF]

Oncologist
Kotani D, Inoue E, Denda T, Inagaki C, Kashiwada T, Mihara Y, Sugaya A, Suwa Y, Ohta T, Kuramochi H, Oshima K, Yuki S, Shiozawa M, Tsuji A, Muro K, Ichikawa W, Fujii M, Sunakawa Y.   +17 more
europepmc   +1 more source

Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma. [PDF]

Commun Biol
Hamis S, Browning AP, Jenner AL, Villa C, Maini PK, Cassidy T.   +5 more
europepmc   +1 more source

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer? [PDF]

J Thorac Dis
Yonesaka K.
europepmc   +1 more source

Eruptive nevi in the setting of encorafenib: A case report and literature review

JAAD Case Reports
Marisa Lenga, BS, Samantha Venkatesh, MD, Jennifer Nam Choi, MD   +2 more
doaj   +1 more source

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. [PDF]

iScience
Shu Y, Shi F, Xiong J, Zheng J, Ding Y, Zhang W, Xu P, Zhang Q.   +7 more
europepmc   +1 more source

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series. [PDF]

Front Endocrinol (Lausanne)
Yamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N, Finkel I.   +10 more
europepmc   +1 more source

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancer. [PDF]

Future Oncol
Kopetz S, Tabernero J, Élez E.
europepmc   +1 more source

Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug Testing. [PDF]

ACS Appl Bio Mater
Vázquez-Aristizabal P, Arriola-Alvarez I, Henriksen-Lacey M, Alonso-Martin S, van den Broek L, Liz-Marzán LM, Izeta A.   +6 more
europepmc   +1 more source

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. [PDF]

Nat Commun
Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A.   +28 more
europepmc   +1 more source